<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557206</url>
  </required_header>
  <id_info>
    <org_study_id>OX-04-033</org_study_id>
    <secondary_id>VA-CORNET</secondary_id>
    <nct_id>NCT00557206</nct_id>
  </id_info>
  <brief_title>Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer</brief_title>
  <official_title>Multicenter Phase II Trial of Oxaliplatin and Docetaxel for Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minneapolis Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Minneapolis Veterans Affairs Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient receiving oxaliplatin and docetaxel will have longer progression free survival than
      those patients receiving standard care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxaliplatin: 130mg/m2 given on day 1 by intravenous injection; and Docetaxel: 60mg/m2 given
      on day 1 by intravenous injection

      Cycles are repeated every 21 days until disease progression, unacceptable toxicity or
      subject's withdrawal.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding was terminated
  </why_stopped>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate as determined by RECIST criteria every 6 weeks.</measure>
    <time_frame>2 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity and Quality of Life assessments every 3 weeks.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Neoplasms</condition>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single arm trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin and Docetaxel</intervention_name>
    <description>Chemotherapy
Oxaliplatin 130mg/m2 on day 1; and Docetaxel 75mg/m2 on day 1; every 21 days.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed metastatic or locoregionally recurrent SCCHN
             deemed incurable by local therapy

          -  Measureable disease

          -  No prior use of palliative chemo after the SCCHN is deemed incurable by local therapy

          -  No prior treatment with oxaliplatin or docetaxel

          -  18 years of age or older

          -  ECOG Performance status 0-1

          -  ANC 1,500/mcl or greater

          -  Adequate renal function

          -  Adequate liver function

          -  Recovered from acute and late effects of any prior treatment with a minimum of 4 weeks
             from the last session to enrollment in the study

          -  Patient or their legal representative must be able to read, understand, and provide
             informed consent

          -  Patients of childbearing potential and their partners must agree to use an effective
             form of contraception during the study and for 90 days following the last dose of
             study medication

        Exclusion Criteria:

          -  Patients with an active documented infection or with a fever (38.5 degrees celsius or
             higher) within 3 days of the first scheduled dose of study treatment

          -  Patients with active CNS metastases

          -  Hypercalcemia related to SCCHN

          -  History of prior malignancy with the past 5 years except for curatively treated basal
             cell carcinoma of the skin, cervical intraepithelial neoplasia or localized prostate
             cancer

          -  Patients with known hypersensitivity to any of the components of oxaliplatin or
             docetaxel or to other drugs formulated with polysorbate 90

          -  Patients receiving concurrent investigational therapy or investigational therapy less
             than 30 days from first scheduled dose of study therapy

          -  Peripheral neuropathy grade 2 or higher

          -  Any medical condition deemed by the Investigator to be likely to interfere with a
             patient's ability to sign informed consent, cooperate and participate in the study, or
             interfere with the interpretation of the results

          -  History of allogeneic transplant

          -  Known HIV or Hepatitis B or C (active, previously treated or both)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Balkrishna Jahagirdar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis Veterans Affairs Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicki A Morrison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis Veterans Affairs Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Degardin M, Cappelaere P, Krakowski I, Fargeot P, Cupissol D, Brienza S. Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol. 1996 Jul;32B(4):278-9.</citation>
    <PMID>8776427</PMID>
  </reference>
  <reference>
    <citation>Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drug approval summaries: oxaliplatin. Oncologist. 2004;9(1):8-12.</citation>
    <PMID>14755010</PMID>
  </reference>
  <reference>
    <citation>Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003 Aug;30(4 Suppl 15):5-13. Review.</citation>
    <PMID>14523789</PMID>
  </reference>
  <reference>
    <citation>Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996 Dec 24;52(12):1855-65.</citation>
    <PMID>8951344</PMID>
  </reference>
  <reference>
    <citation>Kollmannsberger C, Rick O, Derigs HG, Schleucher N, Schöffski P, Beyer J, Schoch R, Sayer HG, Gerl A, Kuczyk M, Spott C, Kanz L, Bokemeyer C. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2002 Apr 15;20(8):2031-7.</citation>
    <PMID>11956262</PMID>
  </reference>
  <reference>
    <citation>Dieras V, Bougnoux P, Petit T, Chollet P, Beuzeboc P, Borel C, Husseini F, Goupil A, Kerbrat P, Misset JL, Bensmaïne MA, Tabah-Fisch I, Pouillart P. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. Ann Oncol. 2002 Feb;13(2):258-66.</citation>
    <PMID>11886003</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2007</study_first_submitted>
  <study_first_submitted_qc>November 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2007</study_first_posted>
  <last_update_submitted>November 4, 2013</last_update_submitted>
  <last_update_submitted_qc>November 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Minneapolis Veterans Affairs Medical Center</investigator_affiliation>
    <investigator_full_name>Balkrishna Jahagirdar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Recurrent Disease</keyword>
  <keyword>Metastatic Disease</keyword>
  <keyword>Squamous Cell Carcinoma</keyword>
  <keyword>Multicenter</keyword>
  <keyword>Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

